Diligence memo · auto-generated · as of July 2, 2026

Spearhead Bio, Inc.

Spearhead Bio, Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Spearhead Bio, Inc. operates in Biotech / Pharma, based in SAINT LOUIS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Spearhead Bio, Inc. has raised $1.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.0M on 2025-02-06.

Most recent recorded round closed around 2025-02-06.

Valuation (modeled)modeled

Provath models Spearhead Bio, Inc. at approximately $3.6M (range $756K–$8.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.00× the median modeled value of Seed Biotech / Pharma companies in 2025–2027 (5 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 17 mo ago; this sector typically re-raises about every 15 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 31% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 21% of those peers.

Closest niche peers: Pluto Biosciences, Inc., Chirality Biosciences, Inc., PharmaWaste Ventures, LLC, Catch Bio, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.